Prostate precision MDxHealth focuses on urology-focused precision diagnostics with tests leveraging genetic, epigenetic, and other molecular technologies to personalize prostate cancer diagnosis, prognosis, and treatment response, presenting a clear cross-sell opportunity to oncologists and urology clinics.

Strategic refocus The company announced a strategic exit from the Resolve UTI testing line and plans to close a Plano, Texas lab to sharpen its focus on prostate cancer diagnostics, suggesting sales efforts should prioritize core prostate cancer offerings and related services.

Evidence foundation A peer‑reviewed Oxford GPS-ProMPT study publication strengthens clinical credibility for the GPS-ProtecT trial, creating a compelling value proposition for outcomes-driven sales conversations with hospitals, academic centers, and payer discussions.

Nasdaq readied Recent Nasdaq minimum bid price deficiency notification indicates near-term needs around capitalization and market visibility; engage with investor relations to leverage broader visibility for partnerships, collaborations, and potential channel opportunities.

Global footprint Headquartered in the US with European base and Netherlands lab operations, MDxHealth offers multinational reach that can support cross-border clinical collaborations, multi-site studies, and payer negotiations across Europe and North America.